Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report

RATIONALE: Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk associated with immune effector cell-associated neurotoxicity syndrome and pseudoprogression, patients with central nervous s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yagi, Yu, Kanemasa, Yusuke, Ohigashi, An, Morita, Yuka, Tamura, Taichi, Nakamura, Shohei, Otsuka, Yuki, Kishida, Yuya, Kageyama, Akihiko, Shimizuguchi, Takuya, Toya, Takashi, Shimizu, Hiroaki, Najima, Yuho, Kobayashi, Takeshi, Haraguchi, Kyoko, Doki, Noriko, Okuyama, Yoshiki, Omuro, Yasushi, Shimoyama, Tatsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568412/
https://www.ncbi.nlm.nih.gov/pubmed/34871273
http://dx.doi.org/10.1097/MD.0000000000027733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568412/
https://www.ncbi.nlm.nih.gov/pubmed/34871273
http://dx.doi.org/10.1097/MD.0000000000027733

Ejemplares similares